Johnson & Johnson (JNJ)

Re: Johnson & Johnson (JNJ)

Postby winston » Fri Jul 27, 2018 8:19 am

not vested

For Retirees: Johnson & Johnson

You have undoubtedly used a Johnson & Johnson (JNJ - Get Report) product in your life at some point, and your grandparents more than likely have, too. It's almost unescapable with a company with a market cap of more than $300 billion.

The blue-chip stock's staying power and brand recognition should be viewed favorably by retiree investors, says Robert Johnson, principal at the Fed Policy Investment Research Group.

Demand for Johnson & Johnson's products remains fairly consistent, providing a more stable investment in the event of a stock market decline, Johnson thinks.

J&J has increased its dividend for 55 consecutive years and currently has a yield of 2.90%. It's highly likely J&J will continue to hike its dividend in the years to come.

"It's a company that will still sell its products," says Matt Hylland, founder of Hylland Capital Management.

Source: The Street
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Johnson & Johnson (JNJ)

Postby winston » Thu Oct 18, 2018 6:23 am

not vested

Johnson & Johnson books US$3.9b quarterly profit

Johnson & Johnson is edging out profit and revenue expectations for the third quarter and raising its profit outlook as domestic sales rise.

The company today reported third-quarter earnings of US$3.93 billion, or US$1.44 per share. Earnings, adjusted for one-time gains and costs, were US$2.05 per share, or 2 US cents better than expected, according to a survey by Zacks Investment Research.

Revenue was US$20.35 billion, also exceeding forecasts.

Johnson & Johnson expects full-year earnings in the range of US$8.13 to US$8.18 per share, with revenue in the range of US$81 billion to US$81.4 billion.

Source: AP

http://www.thestandard.com.hk/breaking- ... r=20181016
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Johnson & Johnson (JNJ)

Postby winston » Wed Dec 05, 2018 10:46 am

not vested

Defensive Stocks to Buy for 2019: Johnson & Johnson (JNJ)
Dividend Yield: 2.4%

Due to the volatile news cycle, most investors are considering healthcare companies among the best stocks to buy for 2019. I can’t argue with that logic. Irrespective of economic factors or a potential trade deal, people need access to medical care.

But in terms of far-reaching defensive stocks, I don’t think you can beat Johnson & Johnson (NYSE:JNJ). Earlier this year, I covered the company’s second-quarter fiscal 2018 earnings report, which produced a solid profitability beat.

More impressively, this wasn’t a disjointed performance. While its pharmaceuticals division was the runaway leader, medical devices and consumer goods achieved decent results.

Furthermore, we’re seeing the rewards play out in the markets. Since the second-half of the year, JNJ stock has gained over 22%. Due to the significant upside momentum, shares are now up 8% for the year.

Finally, we can’t ignore its 2.4% dividend yield. With JNJ stock, investors can benefit from a resurgent company that offers protection in the form of passive income.

Source: Investor Place
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Johnson & Johnson (JNJ)

Postby winston » Sat Dec 15, 2018 11:22 am

not vested

Safe Stocks to Buy on the Defensive: Johnson & Johnson (JNJ)

After having a rough go in the first half of the year, JNJ stock has soared back to life in the second half.

Since July’s opening price, shares have rocketed over 23%. Not only that, JNJ pays a relatively generous dividend at 2.4%.

Moreover, I agree with our own Bret Kenwell, who recently wrote that “JNJ has an A+ balance sheet and a business model that, while not totally impervious to economic trends, holds its own in good times and bad times.”

Plus, with its multi-faceted revenue streams, JNJ is easily one of your top safe stocks to buy.

Source: Investor Place
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Johnson & Johnson (JNJ)

Postby winston » Tue Dec 18, 2018 9:06 pm

not vested

Let's Get Real About Johnson & Johnson's Selloff and How to Play the Stock

I find a lot of Reuters' claims hard to believe. Even more difficult to believe is the selloff.

By TIMOTHY COLLINS

J&J is facing a group of 11,700 plaintiffs claiming their product contained asbestos and caused cancer.

If this plays out in court, the burden of proof lies with the plaintiffs, which means they will have to do something that has never been done: scientifically show a causal link between baby powder usage and cancer.

If we assume the market cap cut (around $40 billion give-or-take the fast market moves), that works out to around $3 million+ per claimant. Again, possible, but not likely.


I believe that $125 level would be our short-term strong support, although I find JNJ attractive here.

I would approach JNJ with a "buy half" mentality. Buy half a position Monday, then consider adding should it drop into the $105-115 range. Otherwise, simply enjoy a well-timed buy if the stock continues to rise.


Source: The Street

https://realmoney.thestreet.com/investi ... yptr=yahoo
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Johnson & Johnson (JNJ)

Postby winston » Wed Jan 23, 2019 8:32 am

not vested

A rare opportunity

by George Budwell

President Trump's promise to lower prescription drug prices has weighed heavily on the shares of top pharmaceutical companies like Johnson & Johnson this year.

Specifically, the pharma giant's shares have lost 11.4% of their value so far this year, making them absurdly cheap in my view.

J&J's shares are now trading at an attractive 14.4 times forward-looking earnings. And while that particular valuation metric alone suggests that J&J's stock is a bargain compared to the broader field of big pharmas, I think there's so much more here that makes this stock too cheap to ignore right now.

First off, J&J is quickly catching up to the leaders in the high-growth field of immuno-oncology. Although the company initially lagged behind the pioneers in this space, J&J jumped in with both feet via a licensing deal with a Chinese company called Legend Biotech late last year.

The two companies are currently developing a potentially best-in-class chimeric antigen receptor T-cell candidate, LCAR-B38M, for advanced multiple myeloma. In an early stage study last year, LCAR-B38M generated a stunning 100% response rate in patients whose multiple myeloma returned after previous treatments.

This experimental therapy therefore has a real shot at becoming the standard of care for advanced multiple myeloma, which should translate into some truly astounding sales figures down the road.

In addition, J&J also sports several other potential blockbuster candidates within its broader portfolio, giving it one of the most valuable clinical pipelines in the industry.

Apart from J&J's stellar pipeline, the company also offers one of the best dividend programs in all of healthcare, an AAA-rated balance sheet, and a mountain of cash that can be used for business development going forward.

So there's a lot to like about J&J in both the short and long term, and that's why I think investors would be wise to take advantage of this exceedingly rare dip in J&J's stock price.

Source: Motley Fool
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Johnson & Johnson (JNJ)

Postby winston » Sun Jun 02, 2019 3:09 pm

not vested

Johnson & Johnson (NYSE:JNJ) shares are continuing to fall further away from their 200-day moving average, closing in on their January lows to exit a four-month consolidation range.

The stock is being weighed down by the start of a first-of-its-kind opioid liability lawsuit in Oklahoma and reports of a $300 million judgement in a New York lawsuit over its talc powder.

The company will next report results on July 16 before the bell.

Analysts are looking for earnings of $2.40 on revenues of $20.3 billion.

When the company last reported on April 16, earnings of $2.10 beat estimates by six cents on a 0.1% rise in revenues.

Source: Investor Place
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Johnson & Johnson (JNJ)

Postby winston » Mon Jun 17, 2019 4:24 pm

not vested

Johnson & Johnson (JNJ)

This one is a traditional defensive stock, and it has a reputation for being a bit staid, but don’t let that fool you: Johnson & Johnson offers real value, consistently delivering on both dividend and long-term equity growth. Both are markers of a strong defensive play.

The company’s current dividend yield is 2.72%, which may seem small, but at current share prices it equates to an annual payout of $3.80.

Better than the actual dividend payment, however, is JNJ’s dividend history. The company has been paying, and steadily increasing, its dividend since the early 1970s. This policy of consistently rewarding shareholders provides a steady source of income for investors, and also encourages them to reinvest that income in the company. It’s a win-win policy.

As a long-term investment, JNJ has, like Apple, proven its worth. The stock has gained 56% in the last 5 years, and shows a 9% gain over the past 12 months. And also like Apple, JNJ has proven resilient in the face of adversity: last December, the stock took a hard hit from bad press related to the widely reported talcum powder recall, but has since regained most of that loss.

In another example of corporate resiliency, JNJ was recently given a buy rating with a $157 price target by five-star analyst Joanne Wuensch (Track Record & Ratings) of BMO Capital, after she reviewed the status of current legal action the company faced in the state of Oklahoma in regard to the opioid abuse epidemic.

Wuensch notes that the case will likely be resolved quickly, and points out, “Litigation is a common occurrence in the health care sector that takes significant time to resolve, and often headlines are worse than reality.” Her price target indicates confidence in the stock, and a 12% upside.

Johnson & Johnson’s success rests on two separate bases. The first, and most widely recognized, is the company’s array of popular consumer brands. JNJ is the producer of Band-Aids, Listerine, and Tylenol, to name just a few.

Consumer products provide a respectable 16.7% of annual revenue (nearly $14 billion), but the real money for JNJ lies in pharmaceuticals. To put it in perspective, two drugs – Remicade and Simponi – account for 11.3% of the company’s total revenues, two-thirds as much as all of the consumer products.

Unlike many large-scale drug producers, Johnson & Johnson is not deeply exposed to payment issues with the Medicare and Medicaid systems. This is important for investors, as both programs have reputations for underpaying, and with an election year coming up both programs are likely to become political footballs as candidates promise ever more benefits.

This is a key point noted by Terence Flynn (Track Record & Ratings). Writing for Goldman Sachs, Flynn says, “The company has the lowest exposure to Medicare/Medicaid within the group. As a result, the stock will be less impacted by potential drug pricing headlines/policy proposals ahead of the 2020 presidential election.” Flynn sets a price target of $163 for JNJ, suggesting an upside of 16%.

JNJ’s consensus rating of ‘Moderate Buy’ is derived from 7 buy and 5 hold reviews. The stock’s $149 average price target and $140 share price equate to an upside potential of 7%.

Source: Tip Ranks
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Johnson & Johnson (JNJ)

Postby winston » Fri Aug 16, 2019 3:19 pm

not vested

Johnson & Johnson (JNJ)

So this is where homework is crucial. JNJ stock sells at a 22 trailing P/E and 4.2 times sales. This is not cheap, but it’s not bloated either.

Over the past five years, JNJ stock teetered around $125 per share. So as it falls into this area again, these zones are usually support because bulls and bears will fight over them again.

There is technical risk. If JNJ loses that pivot level then it could retest $115 per share. Although it is not a forecast, it is a bearish scenario that exists below.

I cannot confirm that JNJ stock is as cheap as it’s going to be. But I can confirm that it probably won’t matter. In the long run, I am confident that holding Johnson & Johnson stock is likely to have more upside potential than downside risk from these levels.

The idea of buying stocks on dips is almost never going to be perfect. But here’s an emphatic statement: If the stock markets are higher in the future then so are GOOGL, AAPL and JNJ stock.

Nevertheless, since we still have a slew of geopolitical risk booming, I don’t enter trades in full size today. It is always best to take positions in tranches, which leaves room for adjustments wherever necessary.

Source: Investor Place
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 118527
Joined: Wed May 07, 2008 9:28 am

Re: Johnson & Johnson (JNJ)

Postby behappyalways » Tue Aug 27, 2019 6:10 pm

Opioid crisis: Johnson & Johnson hit by landmark ruling
https://www.bbc.com/news/business-49452373
血要热 头脑要冷 骨头要硬
behappyalways
Millionaire Boss
 
Posts: 39914
Joined: Wed Oct 15, 2008 4:43 pm

PreviousNext

Return to E to K

Who is online

Users browsing this forum: No registered users and 7 guests

cron